DarioHealth Corp（DRIO）の財務DRIODarioHealth Corp

Evaluating the bottom line, DarioHealth Corp maintains a gross margin of 61.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -125.15%, while the net margin is -153.06%. These profitability ratios, combined with a Return on Equity (ROE) of -104.37%, provide a clear picture of how effectively DRIO converts its operational activities into shareholder value.

In the context of the broader market, DRIO competes directly with industry leaders such as NNOX and MDXH. With a market capitalization of $74.33M, it holds a significant position in the sector. When comparing efficiency, DRIO's gross margin of 61.66% stands against NNOX's -60.03% and MDXH's 59.79%. Such benchmarking helps identify whether DarioHealth Corp is trading at a premium or discount relative to its financial performance.

DarioHealth reported a net loss of $7.92 million in Q2 2026, a significant improvement from the previous year's loss of $18.56 million. The gross margin has improved to 61.66%, indicating better cost management.